Literature DB >> 33409159

Nitrofurantoin Combined With Amikacin: A Promising Alternative Strategy for Combating MDR Uropathogenic Escherichia coli.

Zi-Xing Zhong1,2, Ze-Hua Cui1,2, Xiao-Jie Li3, Tian Tang1,2, Zi-Jian Zheng1,2, Wei-Na Ni1,2, Liang-Xing Fang1,2, Yu-Feng Zhou1,2, Yang Yu1,2, Ya-Hong Liu1,2,4, Xiao-Ping Liao1,2,4, Jian Sun1,2,4.   

Abstract

Urinary tract infections (UTI) are common infections that can be mild to life threatening. However, increased bacterial resistance and poor patient compliance rates have limited the effectiveness of conventional antibiotic therapies. Here, we investigated the relationship between nitrofurantoin and amikacin against 12 clinical MDR uropathogenic Escherichia coli (UPEC) strains both in vitro and in an experimental Galleria mellonella model. In vitro synergistic effects were observed in all 12 test strains by standard checkerboard and time-kill assays. Importantly, amikacin or nitrofurantoin at half of the clinical doses were not effective in the treatment of UPEC infections in the G. mellonella model but the combination therapy significantly increased G. mellonella survival from infections caused by all 12 study UPEC strains. Taken together, these results demonstrated synergy effects between nitrofurantoin and amikacin against MDR UPEC.
Copyright © 2020 Zhong, Cui, Li, Tang, Zheng, Ni, Fang, Zhou, Yu, Liu, Liao and Sun.

Entities:  

Keywords:  G. mellonella model; MDR UPEC; amikacin; antibiotic combination; nitrofurantoin

Year:  2020        PMID: 33409159      PMCID: PMC7779487          DOI: 10.3389/fcimb.2020.608547

Source DB:  PubMed          Journal:  Front Cell Infect Microbiol        ISSN: 2235-2988            Impact factor:   5.293


  54 in total

1.  Uncovering novel susceptibility targets to enhance the efficacy of third-generation cephalosporins against ESBL-producing uropathogenic Escherichia coli.

Authors:  Minh-Duy Phan; Amy L Bottomley; Kate M Peters; Elizabeth J Harry; Mark A Schembri
Journal:  J Antimicrob Chemother       Date:  2020-06-01       Impact factor: 5.790

2.  High admission prevalence of fluoroquinolone resistance in third-generation cephalosporin-resistant Enterobacteriaceae in German university hospitals.

Authors:  Anna M Rohde; Miriam Wiese-Posselt; Janine Zweigner; Frank Schwab; Alexander Mischnik; Harald Seifert; Petra Gastmeier; Winfried V Kern
Journal:  J Antimicrob Chemother       Date:  2018-06-01       Impact factor: 5.790

3.  The Global Prevalence of Class 1 Integron and Associated Antibiotic Resistance in Escherichia coli from Patients with Urinary Tract Infections, a Systematic Review and Meta-Analysis.

Authors:  Mehrdad Halaji; Awat Feizi; Arezoo Mirzaei; Hadi Sedigh Ebrahim-Saraie; Amirhossein Fayyazi; Ali Ashraf; Seyed Asghar Havaei
Journal:  Microb Drug Resist       Date:  2020-04-13       Impact factor: 3.431

Review 4.  Urinary tract infections: current and emerging management strategies.

Authors:  Amelia E Barber; J Paul Norton; Adam M Spivak; Matthew A Mulvey
Journal:  Clin Infect Dis       Date:  2013-05-03       Impact factor: 9.079

Review 5.  Aminoglycoside drugs in clinical practice: an evidence-based approach.

Authors:  Leonard Leibovici; Liat Vidal; Mical Paul
Journal:  J Antimicrob Chemother       Date:  2008-11-19       Impact factor: 5.790

6.  The Uropathogenic Escherichia coli Subclone Sequence Type 131-H30 Is Responsible for Most Antibiotic Prescription Errors at an Urgent Care Clinic.

Authors:  Veronika Tchesnokova; Kim Riddell; Delia Scholes; James R Johnson; Evgeni V Sokurenko
Journal:  Clin Infect Dis       Date:  2019-02-15       Impact factor: 9.079

Review 7.  Collateral sensitivity of antibiotic-resistant microbes.

Authors:  Csaba Pál; Balázs Papp; Viktória Lázár
Journal:  Trends Microbiol       Date:  2015-03-25       Impact factor: 17.079

8.  Optimization and Characterization of a Galleria mellonella Larval Infection Model for Virulence Studies and the Evaluation of Therapeutics Against Streptococcus pneumoniae.

Authors:  Freya Cools; Eveline Torfs; Juliana Aizawa; Bieke Vanhoutte; Louis Maes; Guy Caljon; Peter Delputte; Davie Cappoen; Paul Cos
Journal:  Front Microbiol       Date:  2019-02-21       Impact factor: 5.640

9.  Molecular mechanisms of collateral sensitivity to the antibiotic nitrofurantoin.

Authors:  Roderich Roemhild; Marius Linkevicius; Dan I Andersson
Journal:  PLoS Biol       Date:  2020-01-27       Impact factor: 8.029

10.  Antibiotic resistance, virulence factors and genotyping of Uropathogenic Escherichia coli strains.

Authors:  Maryam Raeispour; Reza Ranjbar
Journal:  Antimicrob Resist Infect Control       Date:  2018-10-03       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.